Cardiac Amyloidosis: Hospitals Launch Screening Campaign for “Chameleon Disease

France is launching a nationwide screening campaign across 50 hospitals to detect cardiac amyloidosis, a rare and potentially fatal condition affecting approximately 10,000 people nationwide. The initiative targets a disease often called the “chameleon malady” because its early warning signs mimic unrelated rheumatic and auditory issues years before damaging the heart.

While the World Day Against Cardiac Amyloidosis was marked on October 26, the coordinated hospital screening effort rolled out in late October and early November 2026. The campaign seeks to catch the condition before protein deposits transform the heart into what specialists describe as a rigid muscle incapable of pumping effectively.

Early Symptoms That Appear Years Before Heart Failure

The primary hurdle in diagnosing cardiac amyloidosis lies in its deceptive presentation. Abnormal protein deposits infiltrate joints and nerves up to a decade before hitting the cardiovascular system, as explained by Thibault Damy, a cardiologist and national reference for amyloidosis screening at Assistance publique des hôpitaux de Paris (AP-HP).

Patients frequently consult orthopedic surgeons or rheumatologists long before seeing a cardiologist. Common early indicators include carpal tunnel syndrome, sudden tendon ruptures, trigger fingers, hip or knee osteoarthritis, joint pain, and progressive hearing loss. Shamir Vally, a cardiologist at CHU Félix Guyon and responsible for the amyloid network in La Réunion, noted that these signs typically emerge in individuals over the age of 50.

If left unchecked, the disease eventually progresses to heart stiffness, resulting in severe fatigue, swollen legs, and shortness of breath. Michel, an 83-year-old patient at Henri-Mondor Hospital in Créteil, discovered his condition only after undergoing surgery for hand tingling and a double carpal tunnel operation, narrowly avoiding advanced heart failure thanks to a vigilant hand surgeon.

Survival Rates and the Impact of Early Diagnosis

Survival rates increase by 40% when medical teams catch cardiac amyloidosis early. Despite this window of opportunity, the average diagnostic delay in France spans two to four years.

Medical professionals aim to shorten this timeline by educating orthopedic specialists and rheumatologists to spot the non-cardiac warning signs. When multiple musculoskeletal or auditory symptoms cluster together, physicians recommend a prompt cardiological evaluation involving an electrocardiogram and an echocardiography. Catching the condition at the rheumatic stage allows doctors to deploy stabilizing treatments before the heart undergoes irreversible damage.

Frequently Asked Questions About the National Screening Campaign

Which facilities are offering the free screenings?

A network of 50 hospitals across France, including the CHU Félix-Guyon in Saint-Denis and hospital sites in Créteil, are participating in the national prevention campaign.

Who is the primary demographic targeted by this health initiative?

The campaign focuses primarily on adults over the age of 50 who experience persistent or progressive symptoms such as carpal tunnel syndrome, unexplained joint disorders, tendon ruptures, or hearing loss.

How does the medical team test for the chameleon malady?

When multiple non-cardiac warning signs prompt a referral, cardiologists perform an electrocardiogram and an echocardiogram to determine whether abnormal protein infiltration has begun affecting the heart muscle.

More on this story: AHA 2026 Preview: New ATTR-CM Data on Vutrisiran and Eplontersen